Ad
related to: is simvastatin bad for kidneys disease list of names for men mayo clinicGoodRx helps people pay for Rx they otherwise couldn't afford. - Patch
Search results
Results from the WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. [4] It is also used to decrease the risk of heart problems in those at high risk. [4] It is taken by mouth. [4]
No studies have examined the effect of statins on cognition in patients with prior stroke. However, two large studies (HPS and PROSPER) that included people with vascular diseases reported that simvastatin and pravastatin did not impact cognition. [40] Statins have been studied for improving operative outcomes in cardiac and vascular surgery. [41]
Other statins have a small risk of 0.44 cases per 10 000 person-years. [9] Previous chronic kidney disease and hypothyroidism increase the risk of myopathy due to statins. It is also more common in the elderly, those who are severely disabled, and when statins are used in combination with particular other medicines, such as ciclosporin. [14] [9]
Includes factors that can increase the risk of heart disease, such as kidney disease, obesity and a marker of poor blood sugar control (hemoglobin A1C). Calculates risk separately for men and women.
Statins are a medication type that can help people at risk for atherosclerotic cardiovascular disease. Doctors look at several factors to determine if statin therapy makes the most sense for someone.
This article provides a list of autoimmune diseases. These conditions, where the body's immune system mistakenly attacks its own cells, affect a range of organs and systems within the body. Each disorder is listed with the primary organ or body part that it affects and the associated autoantibodies that are typically found in people diagnosed ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Sitagliptin is a dipeptidyl peptidase-4 inhibitor and simvastatin is an HMG-CoA reductase inhibitor. [1] These two disorders commonly occur in people at the same time, and have been typically treated with administration of these medications separately. The combination was approved in 2011, and sold under the brand name Juvisync by Merck ...